Menu
← Oncology Approval Tracker
FDA DECISION ·
Bosaya
denosumab-kyqq · Biocon Biologics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Prolia biosimilar with oncology uses for increasing bone mass in men at high fracture risk on androgen deprivation for nonmetastatic prostate cancer and women at high fracture risk on adjuvant aromatase inhibitors for breast cancer.
LAMPGEN ANALYSIS
Why it matters
This denosumab presentation adds a biosimilar option for bone loss associated with specific breast and prostate cancer hormone treatments.
What research teams should watch
Keep the prevention and bone loss pathways separate in inventory, orders, and patient-facing instructions.
PRIMARY RECORDS